S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

CSCI COSCIENS Biopharma Inc

2.8287

0.0087 (0.31%)

Apr 17 2025 - Closed

Delayed by 15 minutes

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

COSCIENS Biopharma (NASDAQ:CSCI)
Historical Stock Chart
From Mar 2025 to Apr 2025

Click Here for more COSCIENS Biopharma Charts.

COSCIENS Biopharma (NASDAQ:CSCI)
Historical Stock Chart
From Apr 2024 to Apr 2025

Click Here for more COSCIENS Biopharma Charts.

COSCIENS Biopharma Inc News

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Monday 14 April 2025 (4 days ago) • Edgar (US Regulatory)

COSCIENS Biopharma Inc. Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer
Monday 14 April 2025 (4 days ago) • GlobeNewswire Inc.

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
Wednesday 9 April 2025 (1 week ago) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Wednesday 9 April 2025 (1 week ago) • Edgar (US Regulatory)

COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
Wednesday 9 April 2025 (1 week ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Wednesday 2 April 2025 (2 weeks ago) • Edgar (US Regulatory)

COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order
Tuesday 1 April 2025 (2 weeks ago) • GlobeNewswire Inc.

COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents
Wednesday 19 March 2025 (4 weeks ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Thursday 13 March 2025 (1 month ago) • Edgar (US Regulatory)

COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product
Thursday 13 March 2025 (1 month ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Monday 23 December 2024 (4 months ago) • Edgar (US Regulatory)

COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization
Monday 23 December 2024 (4 months ago) • GlobeNewswire Inc.

More COSCIENS Biopharma Inc News Articles

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions